Skip to Content
Merck
  • Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids.

Vitamin D receptor agonist/histone deacetylase inhibitor molecular hybrids.

Bioorganic & medicinal chemistry (2010-05-11)
Marc Lamblin, Basel Dabbas, Russell Spingarn, Rodrigo Mendoza-Sanchez, Tian-Tian Wang, Beum-Soo An, Dao Chao Huang, Richard Kremer, John H White, James L Gleason
ABSTRACT

Incorporation of zinc-binding groups into the side-chain of 1alpha,25-dihydroxyvitamin D(3) (1,25D) fully bifunctional hybrid molecules which act both as vitamin D receptor agonists and histone deacetylase inhibitors. These bifunctional hybrids display in vitro antiproliferative activity against the AT84 squamous carcinoma cell line while lacking the in vivo hypercalcemic effects of 1,25D.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
1α,25-Dihydroxyvitamin D3, ≥97.0% (HPLC)
Sigma-Aldrich
1α,25-Dihydroxyvitamin D3, ≥99% (HPLC)
Sigma-Aldrich
1α,25-Dihydroxyvitamin D2 solution, 100 μg/mL in ethanol, 95% (CP)